目的探討枳術(shù)寬中膠囊聯(lián)合莫沙必利對2型糖尿病胃輕癱患者的療效及其對胃腸激素水平的影響。方法選取三亞市人民醫(yī)院2019年4月-2020年5月收治的128例2型糖尿病胃輕癱患者，按照治療方法將患者分為對照組和觀察組，每組64例。對照組患者餐前口服枸櫞酸莫沙必利片，5 mg/次，3次/d。觀察組在對照組基礎(chǔ)上加用枳術(shù)寬中膠囊，3粒/次，3次/d。兩組療程均為4周。觀察兩組患者的臨床療效，同時比較兩組治療前后的胃輕癱癥狀指數(shù)（GCSI）、半胃排空時間，以及胃泌素（GAS）和胃動素（MOT）的水平變化。結(jié)果治療后，觀察組總有效率為90.6%，顯著高于對照組的76.6%（P<0.05）。治療后，兩組GCSI評分和半胃排空時間均顯著減低（P<0.05），且觀察組GCSI評分和半胃排空時間顯著低于對照組（P<0.05）。治療后，兩組GAS和MOT水平均顯著減低（P<0.05）；觀察組GAS和MOT顯著低于對照組（P<0.05）。結(jié)論枳術(shù)寬中膠囊聯(lián)合莫沙必利可以顯著抑制糖尿病胃輕癱患者GAS和MOT水平，增強(qiáng)胃動力，臨床療效顯著，使用安全。

Objective To investigate the effect of Zhizhu Kuanzhong Capsules combined with mosapride on type 2 diabetic gastroparesis and its effect on gastrointestinal hormone levels. Methods A total of 128 patients with type 2 diabetic gastroparesis admitted to Sanya People's Hospital from April 2019 to May 2020 were selected. According to the treatment methods, the 128 patients were divided into control group and observation group, with 64 patients in each group. Patients in the control group were po administered with Mosapride Citrate Tablets before meal, 5 mg/time, three times daily. Patients in the observation group were po administered with Zhizhu Kuanzhong Capsules on the basis of control group, 3 grains/time, three times daily. The treatment course of both groups was 4 weeks. The clinical efficacy of two groups was observed, and the changes of gastroparesis symptom index (GCSI), GAS and MOT levels before and after treatment were compared between two groups. Results After treatment, the total effective rate of observation group was 90.6%, which was significantly higher than 76.6% of control group (P < 0.05). After treatment, GCSI score and hemigastric emptying time in two groups were significantly decreased (P < 0.05), and GCSI score and hemigastric emptying time in the observation group were significantly lower than those in the control group (P < 0.05). After treatment, the levels of GAS and MOT in two groups were significantly decreased (P < 0.05). And the levels of GAS and MOT in observation group were significantly lower than those in control group (P < 0.05). Conclusion Zhizhu Kuanzhong Capsules combined with mosapride can significantly inhibit the levels of GAS and MOT in patients with diabetic gastroparesis, enhance gastric motility, with significant clinical efficacy and safe use.

R975

海南省衛(wèi)生計生行業(yè)科研項(xiàng)目（16A200069）